Physician profile
Stuart Tashman
NPI 1760469779
$1,509.26
in general payments reported to CMS, 2019-2025
21 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.98 · 2020: $87.92 · 2021: $236 · 2022: $270 · 2023: $472 · 2024: $172 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740 · Education: $79.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.40 |
| Education | $79.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $390.61 | 2019-2025 | Bexsero, Rotarix, Penmenvy |
| Merck Sharp & Dohme LLC | $211.59 | 2021-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $186.21 | 2021-2025 | |
| Sanofi Pasteur INC. | $119.27 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.48 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $79.74 | 2023-2025 | Rayaldee |
| Ironshore Pharmaceuticals INC. | $51.02 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $50.71 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $46.50 | 2023 | Kristalose |
| Corium, LLC | $44.45 | 2022-2023 | Azstarys |
| Shire North American Group INC | $34.92 | 2019 | |
| Verrica Pharmaceuticals INC. | $28.30 | 2024 | Ycanth |
| Genzyme Corporation | $26.03 | 2023 | |
| Exact Sciences Corporation | $20.19 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $18.93 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $18.40 | 2023 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $17.58 | 2024 | Farxiga |
| Travere Therapeutics, INC. | $16.31 | 2023 | Cholbam |
| Adlon Therapeutics L.P. | $15.64 | 2020 | |
| Cranial Technologies, INC | $15.25 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $15.13 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Tashman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.